Alphina Therapeutics, a biotechnology company developing a best-in-class NAMPT inhibitor for the treatment of a range of solid tumor indications, has appointed Nick Galli as chief executive officer and a member of the board of directors.   Galli brings nearly twenty years of private and public pharmaceutical and biotechnology industry experience with a focus on strategy, company building, and business development. As an executive, he has helped biotech companies raise over $450 million in equi...